The 20 analysts offering 12-month price forecasts for Edwards Lifesciences Corp have a median target of 131.50, with a high estimate of 140.00 and a low estimate of 99.00. The median estimate represents a +35.82% increase from the last price of 96.82.
The current consensus among 25 polled investment analysts is to Buy stock in Edwards Lifesciences Corp. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.64
Reporting Date Jul 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.